Ziprasidone — Membership Pricing

Other medications in Mental Health

• Zuranolone
• Acamprosate
• Alprazolam
• Amphetamine Salts
• Aripiprazole
• Asenapine
• Atomoxetine
• Brexanolone

About Ziprasidone

Ziprasidone is an important medication often prescribed for serious mental health conditions. At TheDrugClub, we understand the financial burden these prescriptions can represent. Our mission is to make essential medications like ziprasidone more accessible and affordable for our members, helping you manage your health without breaking the bank. Discover how you can save on your ziprasidone prescription today.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ziprasidone is approved for (FDA label)

Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions ( 5.3 ) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death.

Source: Read the full FDA label on DailyMed. Label effective date: August 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ziprasidone (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ziprasidone (FDA label)

Ziprasidone capsules, USP 40 mg (ziprasidone), are light pink to brown granular powder filled in size “4” hard gelatin capsules having Lavender opaque cap and LT Turquoise blue opaque body, imprinted “RDY” on cap and “257” on body with black ink. Capsules: 40 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ziprasidone (FDA label)

The following adverse reactions are described in more detail in other sections of the prescribinginformation: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions ( 5.2 )] QT Prolongation and Risk of Sudden Death [see Contraindications ( 4.2 ), Warnings and Precautions ( 5.3 )] Serotonin Syndrome [see Contraindications ( 4.3 ), Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.1 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions ( 5.5 )] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.6 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.7 )] Metabolic Changes [see Warnings and Precautions ( 5.8 )] Rash [see Warnings and Precautions ( 5.9 )] Orthostatic Hypotension [see Warnings and Precautions ( 5.10 )] Falls [see Warnings and Precautions ( 5.11 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.12 ) Seizures [see Warnings and Precautions ( 5.13 )] Dysphagia [see Warnings and Precautions ( 5.14 )] Hyperprolactinemia [see Warnings and Precautions ( 5.15 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.16 )] Priapism [see Warnings and Precautions ( 5.17 )] Body Temperature Regulation [see Warnings and Precautions ( 5.18 )] Suicide [see Warnings and Precautions ( 5.19 )] Commonly observed adverse reactions (incidence ≥5% and at least twice the incidence for placebo) were : Schizophrenia: Somnolence, respiratory tract infection. (6.1) Manic and Mixed Episodes Associated with Bipolar Disorder: Somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Dr.

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ziprasidone (FDA label)

Do not use in patients with a known history of QT prolongation (4.1) Do not use in patients with recent acute myocardial infarction (4.1) Do not use in patients with uncompensated heart failure (4.1) Do not use in combination with other drugs that have demonstrated QT prolongation (4.1) Do not use in patients with known hypersensitivity to ziprasidone (4.2) Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (4.3) 4.1 QT Prolongation Because of ziprasidone’s dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, ziprasidone is contraindicated: in patients with a known history of QT prolongation (including congenital long QT syndrome) in patients with recent acute myocardial infarction in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed.

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ziprasidone (FDA label)

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack). (5.2) QT Interval Prolongation : Ziprasidone use should be avoided in patients with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation. (5.3) Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue ziprasidone and serotonergic agents and initiate supportive treatment. (5.4) Neuroleptic Malignant Syndrome (NMS) : Potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring. (5.5) Severe Cutaneous Adverse Reactions, su ch as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome has been reported with ziprasidone exposure. DRESS and other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal.

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ziprasidone (FDA label)

Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation. ( 4.1 , 7.3 ) The absorption of ziprasidone is increased up to two-fold in the presence of food. ( 7.10 ) The full prescribing information contains additional drug interactions. (7) . 7.1 Metabolic Pathway Approximately two-thirds of ziprasidone is metabolized via a combination of chemical reduction by glutathione and enzymatic reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.

Source: FDA prescribing information (DailyMed). Set ID: 6665279a-32ab-43ce-a258-039a6779a1a2. SPL document ID: 5823b8b1-cd0d-ea1f-e063-6294a90aee68. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.